130 related articles for article (PubMed ID: 31073411)
1. Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.
Masui S; Yonezawa A; Izawa K; Hayakari M; Asakura K; Taniguchi R; Isa M; Shibata H; Yasumi T; Nishikomori R; Takita J; Matsubara K
J Pharm Health Care Sci; 2019; 5():9. PubMed ID: 31073411
[TBL] [Abstract][Full Text] [Related]
2. Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature.
Minami N; Nakase H; Yoshino T; Yamada S; Toyonaga T; Honzawa Y; Matsuura M; Chiba T
Clin J Gastroenterol; 2013 Jun; 6(3):226-30. PubMed ID: 26181600
[TBL] [Abstract][Full Text] [Related]
3. Clinical observations on infliximab treatment of infantile onset Takayasu arteritis.
Kang M; Lai J; Zhang D; Xu Y; Zhu J; Li M
Pediatr Rheumatol Online J; 2022 Aug; 20(1):61. PubMed ID: 35927694
[TBL] [Abstract][Full Text] [Related]
4. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
5. [Infliximab in infantile Takayasu arteritis: a case report and literature review].
Li M; Sun XF; Xu YJ; Hou J; Zhang D; Chi Y; Zhu J; Kang M; Li SN; Su GX; Zhou ZX; Lai JM
Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):1001-1005. PubMed ID: 33256323
[No Abstract] [Full Text] [Related]
6. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pediatric Takayasu arteritis with infliximab and cyclophosphamide: experience from an American-Brazilian cohort study.
Stern S; Clemente G; Reiff A; Ramos MP; Marzan KA; Terreri MT
J Clin Rheumatol; 2014 Jun; 20(4):183-8. PubMed ID: 24847743
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab.
Tanimura S; Kato M; Abe N; Ohira H; Tsujino I; Atsumi T
Immunol Med; 2018 Mar; 41(1):39-42. PubMed ID: 30938259
[TBL] [Abstract][Full Text] [Related]
9. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
[TBL] [Abstract][Full Text] [Related]
10. Takayasu arteritis developing during treatment of ulcerative colitis with infliximab.
Horai Y; Satoru O; Lapalme-Remis S; Sumiyoshi R; Nakashima Y; Suzuki T; Okada A; Kawashiri SY; Ichinose K; Tamai M; Yamasaki S; Nakamura H; Takeshima F; Origuchi T; Kawakami A
Mod Rheumatol; 2013 May; 23(3):572-6. PubMed ID: 22718488
[TBL] [Abstract][Full Text] [Related]
11. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate.
Tanaka F; Kawakami A; Iwanaga N; Tamai M; Izumi Y; Aratake K; Arima K; Kamachi M; Nakamura H; Huang M; Ida H; Origuchi T; Eguchi K
Intern Med; 2006; 45(5):313-6. PubMed ID: 16596001
[TBL] [Abstract][Full Text] [Related]
12. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
13. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
[TBL] [Abstract][Full Text] [Related]
15. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods?
Jourdil JF; Lebert D; Gautier-Veyret E; Lemaitre F; Bonaz B; Picard G; Tonini J; Stanke-Labesque F
Anal Bioanal Chem; 2017 Feb; 409(5):1195-1205. PubMed ID: 27826630
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
[TBL] [Abstract][Full Text] [Related]
17. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
[TBL] [Abstract][Full Text] [Related]
18. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
[TBL] [Abstract][Full Text] [Related]
19. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
20. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
